BAXFENDY


What it isAldosterone synthase inhibitor; resistant hypertension.
Why this oneIt blocks aldosterone production rather than its receptor, avoiding spironolactone's antiandrogen effects.
What limits itHyperkalemia requires monitoring and combination with other potassium-raising drugs needs caution; long-term outcome data remain limited.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Hypertension not adequately controlled (add-on) | Adult | 2 mg QD (1 mg QD if increased risk of hyperkalemia or hyponatremia) | 2 mg QD | 2 mg QD |
Renal No adjustment if eGFR ≥45 mL/min (unless at increased hyperkalemia risk); not established for eGFR <45
Hepatic Undefined
Available strengths
Pregnancy No human data; animal embryo-fetal toxicity at high exposures; clinical significance unclear
Lactation No human data; baxdrostat transfers to rat milk
| Strength | #/mo | generic $/mo | CostPlus | |
|---|---|---|---|---|
| 1 mg | tab | 30 qd | not offered | |
| 2 mg | tab | 30 qd | not offered |
Generic entry2040 est.
NO BOXED WARNINGS
Principal riskHyperkalemia; limited long-term data
Legacy pregnancy categoryNot assigned — PLLR-era drug
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.
Open Baxdrostat in the interactive console ↗
